Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;53(4):1698-700.
doi: 10.1128/AAC.01549-08. Epub 2009 Feb 2.

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection

Peter J Petersen  1 , C Hal Jones, Aranapakam M Venkatesan, Patricia A Bradford
Affiliations

Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection

Peter J Petersen et al. Antimicrob Agents Chemother. 2009 Apr.

Abstract

The in vivo efficacy of piperacillin in combination with the penem inhibitor BLI-489 was determined using acute lethal systemic infections in mice. On the basis of preliminary results with various ratios, a dosing ratio of 8:1 was found to be optimal for retention of enhanced efficacy. Piperacillin-BLI-489 dosed at an 8:1 ratio was efficacious against murine infections caused by class A (including extended-spectrum beta-lactamases), class C (AmpC), and class D beta-lactamase-expressing pathogens.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Chemical structure of the penem β-lactamase inhibitor BLI-489.
See this image and copyright information in PMC

References

    1. Barnaud, G., Y. Benzerara, J. Gravisse, L. Raskine, M. J. Sanson-Le Pors, R. Labia, and G. Arlet. 2004. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate. Antimicrob. Agents Chemother. 48:1040-1042. - PMC - PubMed
    1. Barnaud, G., R. Labia, L. Raskine, M. J. Sanson-Le Pors, A. Philippon, and G. Arlet. 2001. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate. FEMS Microbiol. Lett. 195:185-190. - PubMed
    1. Bassetti, M., E. Righi, and C. Viscoli. 2008. Novel β-lactam antibiotics and inhibitor combinations. Expert Opin. Investig. Drugs 17:285-296. - PubMed
    1. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. - PMC - PubMed
    1. Bush, K. 2002. The impact of β-lactamases on the development of novel antimicrobial agents. Curr. Opin. Investig. Drugs 3:1284-1290. - PubMed

LinkOut - more resources